I suspect that the sector could be on pace to a nice recovery this week. Vivek comments this weekend and the FDA commissioner nominee may has allayed some concerns about the incoming administration and their relationship with the sector. I am not completely convinced about anything at this point but what I see it is […]
November 20th Biotech Update
We got the bounce that I was sort of expecting and I would not be surprised if it continued. We are right at pretty strong support (or what I thought should have been pretty strong support). My base case is that we should expect this bounce to continue but I am still not 100% sure […]
November 19th Biotech Update
Well, I was worried about false breakouts and the RFK nomination and both unfortunately came to fruition. We are at a point where support should start to limit the losses. I would actually be a little surprised if we do not get some kind of bounce from the these levels given how far and quickly […]
November 15th Biotech Update
Well, this is why I thought that there was not a clear election outcome that would be all bullish for the sector. The nomination of RFK to head HHS sent the sector down and regardless of what one think about the nomination, it increases uncertainty. He has talked about removing vaccine approvals, blocking others, and […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
